- The stock price of Jupiter Wellness Inc (NASDAQ: JUPW) is trading at over 15% pre-market. This is why it happened.
The stock price of Jupiter Wellness Inc (NASDAQ: JUPW) – a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products – is trading at over 15% pre-market as of 9:11 AM ET. This is why it happened. Investors are responding to Jupiter Wellness announcing the results of a clinical study to investigate the safety and efficacy of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema)
A double-blinded placebo-controlled interventional study was conducted. And subjects were assigned to apply, at home, one of three treatments: JW-100 (a CBD and aspartame combination topical formulation), a CBD only topical formulation, or a placebo topical formulation.
After 14 days, the average reduction in the Investigators Static Global Assessment (ISGA) score was calculated for each group. And the proportion of subjects achieving (ISGA) score 0 (clear) or 1 (almost clear) with at least 2 grade improvement from baseline was recorded for each arm of the study.
In the study, 50% of subjects in the JW-100 arm achieved ISGA clear or almost clear (1 or 2) with at least a 2-grade improvement from baseline after treatment versus 20% and 15% in the CBD-only and placebo arms, respectively. And the percentage of subjects achieving clear or almost clear with at least a 2-grade improvement from baseline was found to be statistically significant (p=0.028).
JW-100 – a novel topical formulation containing CBD and aspartame – was shown to significantly reduce ISGA score in atopic dermatitis patients after two weeks of use. And the combination of CBD and aspartame was more effective at reducing ISGA scores than CBD alone.
KEY QUOTES:
“We are very pleased by the results of the JW-100 study. The results suggest that in future clinical trials, JW-100 may potentially prove superior to existing prescription drugs for the treatment of eczema. On the heels of this study, we plan to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.”
– Jupiter Wellness Chairman and Head of R&D, Dr. Glynn Wilson.
“With the eczema market valued at more than $10 billion in 2020 and a high percentage of patients unsatisfied with their current treatments, we believe Jupiter will be well-positioned to capitalize on the opportunity with our CBD-based proprietary formulation.”
– Jupiter CEO Brian John
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
Recent Comments